Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study

Critical Care Medicine

Volumn 24, Issue 5, 1996, Pages 733-742

  Reinhart, Konrad ^a   Wiegand Löhnert, Carola ^b   Grimminger, Friedrich ^c   Kaul, Martin ^d   Withington, Stuart ^e   Treacher, David ^f   Eckart, Joachim ^g   Willatts, Sheila ^h   Bouza, Carmen ⁱ   Krausch, Dietmar ^b   Stockenhuber, Felix ^j   Eiselstein, Jürgen ^d   Daum, Lothar ^d   Kempeni, Joachim ^d  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c JUSTUS LIEBIG UNIVERSITY   (Germany)

^d Knoll AG   (Germany)

^e ROYAL LONDON HOSPITAL   (United Kingdom)

^f ST THOMAS HOSPITAL   (United Kingdom)

^g Medical Centre   (Germany)

^h BRISTOL ROYAL INFIRMARY   (United Kingdom)

ⁱ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^j UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

Clinical trial; Critical illness; Cytokines; Infection; Interleukin 6; Monoclonal antibodies; Sepsis; Septic shock; Tumor necrosis factor

Indexed keywords

ADRENALIN; ANTIINFECTIVE AGENT; DOBUTAMINE; DOPAMINE; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MAK 195F; NORADRENALIN; PLACEBO; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY RESPONSE; ARTICLE; BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; SEPTIC SHOCK; SURVIVAL;

ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTERLEUKIN-6; LOGISTIC MODELS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SEPSIS; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 9344246862     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003246-199605000-00003     Document Type: Article

References (48)

1. Bone RC: Pathogenesis of sepsis. Ann Intern Med 1991; 115:457-469
2. Wiles JB, Cerra FB, Siegel JH, et al: The systemic septic response: Does the organism matter? Crit Care Med 1980; 8:55-60
3. Natanson C, Danner RL, Elin RJ, et al: Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J Clin Invest 1989; 83:243-251
4. Cerami AC, Beutler B: Role of cachectin TNF in endotoxic shock and cachexia. Immunol Today 1988; 9:28-31
5. Fong Y, Lowry SF: Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin Immunol Immunopathol 1990; 55:157-170
6. Tracey KJ, Fong Y, Hesse DG, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330:662-664
7. Dinarello CA, Wolff SM: The role of interleukin-1 in disease. N Engl J Med 1993; 328:106-113
8. Calandra T, Baumgartner JD, Grau GE, et al: Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha, and interferon-gamma in the serum of patients with septic shock. J Infect Dis 1990; 161:982-987
9. Waage A, Halstensen A, Espevik T: Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; i:355-357
10. Giradin E, Grau GE, Dayer JM, et al: Tumor necrosis factor and interleukin 1 in the serum of children with severe infectious purpura. N Engl J Med 1988; 319:397-400
11. De Groote MA, Martin MA, Densen P, et al: Plasma tumor necrosis factor levels in patients with presumed sepsis. JAMA 1989; 262:249-251
12. Damas P, Ledoux D, Nys M, et al: Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215:356-362
13. Marano MA, Fong Y, Moldawer LL, et al: Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality. Surg Gynecol Obstet 1990; 170:32-38
14. Fiedler VB, Loof I, Sander E, et al: Monoclonal antibody to tumor necrosis factor-α prevents lethal endotoxin sepsis in adult rhesus monkeys. J Lab Clin Med 1992; 120:574-588
15. Alexander HR, Sheppard BC, Jensen JC, et al: Treatment with recombinant human tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of Gram-negative sepsis. J Clin Invest 1991; 88:34-39
16. Exley AR, Cohen J, Buurman W, et al: Monoclonal antibody to TNF in severe septic shock. Lancet 1990; 353:1275-1277
17. Vincent JL, Bakker J, Marcecaux G, et al: Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study. Chest 1992; 101:810-815
18. 2 fragment of an anti-tumor necrosis factor α monoclonal antibody in patients with severe sepsis: Effects on the cardiovascular system and cytokine levels. Shock 1994; 1:1237-1245
19. Fisher CJ, Opal SM, Dhainaut JF, et al: Influence of an antitumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21:318-327
20. Agosti JM, Fisher JC, Opal SM, et al: Treatment of patients with sepsis syndrome with soluble TNF receptor (STNFr). Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy Interscience 1994; 34:65
21. Natanson Ch, Hoffmann WD, Suffredini AF, et al: Anti cytokine therapies. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann Intern Med 1994; 120:771-783
22. Möller A, Emling F, Blohm D, et al: Monoclonal antibodies to human tumor necrosis factor-alpha: In vitro and in vivo application. Cytokine 1990; 2:162-169
23. McCabe WR, Jackson GG: Gram-negative bacteremia. Clinical, laboratory, and therapeutic observations. Arch Intern Med 1962; 110:856-886
24. Knaus WA, Draper EA, Wagner DPO, et al: APACHE II: A severity of disease classification system. Crit Care Med 1985; 13:818-829
25. Goris RJA, Boekhorst TPA, Nuytinck JKS, et al: Multiple organ failure. Arch Surg 1985; 120:1109-1115
26. Bone RC, Fisher CJ, Clemmer TP, et al: Sepsis syndrome: A valid clinical entity. Crit Care Med 1989; 17:389-393
27. Hosmer DW, Lemeshow S: Applied Logistic Regression Analysis. New York, John Wiley & Sons, 1989
28. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143:29-36
29. Bagby GJ, Plessala KJ, Wilson LA, et al: Divergent efficacy of antibody to tumor necrosis factor-α in intravascular and peritonitis models of sepsis. J Infect Dis 1991; 163:83-88
30. Echtenacher B, Falk W, Mannel DN, et al: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 1990; 145:3762-3766
31. Beutler B, Grau GE: Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med 1993; 21(Suppl): S423-S435
32. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al: Treatment of Gram-negative bacteremia in septic shock with HA-1A human monoclonal antibody against endotoxin - A randomized, double-blind, placebo-controlled trial. N Engl J Med 1991; 324:429-436
33. Greenman RL, Schein RM, Martin MA, et al: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991; 266:1097-1102
34. Fisher CJ, Dhainaut JFA, Opal SM, et al: Recombinant human Interleukin 1. Receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 1994; 271:1836-1843
35. Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995; 273:934-941
36. Yusuf S, Wittes J, Probstfield J, et al: Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991; 266:93-98
37. Lowry SF, Calvano SE, van der Poll T: Measurements of inflammatory mediators in clinical sepsis. In: Clinical Trials in Sepsis. Update in Intensive Care and Emergency Medicine. Sibbald WJ, Vincent JL (Eds). Berlin, Heidelberg, New York, Springer Verlag, 1995, pp 86-105
38. Casey LC, Balk RA, Bone RC: Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-778
39. Suter PM, Suter S, Girardin E, et al: High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, inteferon, and elastase in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 1992; 145: 1016-1022
40. Munoz C, Misset B, Fitting C, et al: Dissociation between plasma and monocyte-associated cytokines during sepsis. Eur J Immunol 1991; 21:2177-2184
41. Van der Poll T, Jansen J, van Leenen D, et al: Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 1993; 168:955-960
42. Waage A, Brandtzaeg P, Halstensen A, et al: The complex pattern of cytokines in serum from patients with meningococcal septic shock. J Exp Med 1989; 169:333-338
43. Wortel Ch, von der Möhlen MAM, van Deventer SJH, et al: Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in Gram-negative sepsis: Relation to endotoxin and cytokine levels. J Infect Dis 1992; 166:1367-1374
44. Hack CE, de Groot ER, Felt-Bersma RJF, et al: Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74:1704-1710
45. Munoz C, Carlet J, Fitting C, et al: Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991; 88:1747-1754
46. O Reilly M, Silver GM, Greenhalgh DG, et al: Treatment of intra-abdominal infection with G-CSF. J Trauma 1992; 33:679-682
47. Abraham E, Raffin TA: Sepsis therapy trials. Continued disappointment or reason for hope? JAMA 1994; 271:1876-1878
48. Saravolatz LD, Wherry JC, Spooner C, et al: Clinical safety, tolerability, and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor-α. J Infect Dis 1994; 169:214-217